marketcap
Facebook
Twitter
Telegram
Report an ErrorQuarterly report 2024-Q3
added 11-18-2024
Neoleukin Therapeutics Cash Flow 2011-2024 | NLTX
Annual Cash Flow Neoleukin Therapeutics
| 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Operating Cash Flow |
-51.4 M | -52.8 M | -47.6 M | -24.6 M | -15.4 M | -31.6 M | -44.7 M | -30.2 M | - | - | - | - | - |
Depreciation & Amortization |
3.26 M | 3.2 M | 1.31 M | 785 K | 340 K | 289 K | 360 K | - | - | 136 K | 59.6 K | 131 K | - |
Accounts Payables |
2.6 M | 625 K | 526 K | 1.32 M | 1.6 M | 702 K | 6.02 M | 6.86 M | 2.2 M | 734 K | - | - | - |
Accounts Receivables |
- | - | - | - | - | - | - | - | - | 65.4 K | - | - | - |
Total Inventories |
- | - | - | - | - | - | - | - | - | - | - | - | - |
All numbers in USD currency
Quarterly Cash Flow Neoleukin Therapeutics
| 2024-Q3 | 2024-Q2 | 2023-Q4 | 2023-Q3 | 2023-Q2 | 2023-Q1 | 2022-Q4 | 2022-Q3 | 2022-Q2 | 2022-Q1 | 2021-Q4 | 2021-Q3 | 2021-Q2 | 2021-Q1 | 2020-Q4 | 2020-Q3 | 2020-Q2 | 2020-Q1 | 2019-Q4 | 2019-Q3 | 2019-Q2 | 2019-Q1 | 2018-Q4 | 2018-Q3 | 2018-Q2 | 2018-Q1 | 2017-Q4 | 2017-Q3 | 2017-Q2 | 2017-Q1 | 2016-Q4 | 2016-Q3 | 2016-Q2 | 2016-Q1 | 2015-Q4 | 2015-Q3 | 2015-Q2 | 2015-Q1 | 2014-Q4 | 2014-Q3 | 2014-Q2 | 2014-Q1 | 2013-Q4 | 2013-Q3 | 2013-Q2 | 2013-Q1 | 2012-Q4 | 2012-Q3 | 2012-Q2 | 2012-Q1 | 2011-Q4 | 2011-Q3 | 2011-Q2 | 2011-Q1 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Operating Cash Flow |
- | - | - | - | - | -13 M | - | -34.7 M | -25.4 M | -14.1 M | - | -35.4 M | -26.6 M | -13.4 M | - | -15.3 M | -15.2 M | -6.44 M | - | -10.8 M | -4.23 M | -2.76 M | - | -21.8 M | -6.41 M | -15.6 M | - | -33.1 M | -21.6 M | -11.3 M | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
Depreciation & Amortization |
800 K | 800 K | - | 800 K | 800 K | 329 K | - | 1.19 M | 870 K | 411 K | - | 916 K | 560 K | 247 K | - | 578 K | 390 K | 171 K | - | 180 K | 82 K | 41 K | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | 71.9 K | 18.2 K | - | 45.2 K | 15.6 K | 14.8 K | - | - | - | - | - | - | - | - |
Accounts Payables |
1.68 M | 1.72 M | 2.6 M | - | - | - | - | - | - | - | 526 K | - | - | - | 1.32 M | 3.9 M | - | - | 1.6 M | - | - | - | 702 K | - | - | - | 6.02 M | - | - | - | 6.86 M | - | - | - | 2.2 M | - | - | - | 734 K | - | - | - | 600 K | - | - | - | - | - | - | - | - | - | - | - |
Accounts Receivables |
- | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | 32 K | 19 K | 72 K | 57 K | 65 K | 65 K | 65 K | 65 K | 27.9 K | 27.9 K | 27.9 K | 27.9 K | - | - | - | - | - | - | - | - |
Total Inventories |
- | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
All numbers in USD currency